CM Life Sciences III Inc. just filed a prospectus, suggesting it plans to soon issue some securities

CM Life Sciences III Inc. just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

424B3
1
tmb-20221125x424b3.htm
424B3

​​​PROSPECTUS SUPPLEMENT NO.4Filed Pursuant to Rule 424(B)(3)(to Prospectus dated March 28, 2022)Registration No. 333-261786​​Up to 209,267,414 Shares of Common Stock​Up to 19,733,333 Shares of Common Stock Issuable Upon Exercise of Warrants​Up to 8,693,333 Warrants​This prospectus supplement updates and supplements the prospectus dated March 28, 2022 (the prospectus), which forms a part of our registration statement on Fo rm S-1, as amended (No. 333-261786). This prospectus supplement is being filed to update and supplement the information in the prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on November 25, 2022 (the Form 8-K). Accordingly, we have attached the Form 8-K to this prospectus supplement.​The prospectus and this prospectus supplement relate to the issuance by us of an aggregate of up to 19,733,333 shares of our common stock, $0.0001 par value per share (Common Stock), which consists of (i) up to 8,693,333 shares of Common Stock that are issuable upon the exercise of 8,693,333 warrants (the Placement Warrants) originally issued in a private placement in connection with the initial public offering of CM Life Sciences III Inc. (CMLS) by the holders thereof and (ii) up to 11,040,000 shares of Common Stock that are issuable upon the exercise of 11,040,000 warrants (the Public Warrants and, together with the Placement Warrants, the Warrants) originally issued in the initial public offering of CMLS by the holders thereof. We will receive the proceeds from any exercise of any Warrants for cash.​The prospectus and this prospectus supplement also relate to the offer and sale from time to time by the selling securityholders named in the prospectus (the Selling Securityholders) of (i) up to 209,267,414 shares of Common Stock (including up to 8,693,333 shares of Common Stock that may be issued upon exercise of the Placement Warrants) and (ii) up to 8,

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CM Life Sciences III Inc. makes a similar move, sign up!